Limited availability of RoActemra (Roche): recommendations for (hospital) pharmacists, general practitioners and physician specialists.
August 17, 2021
The stock of RoActemra, a medicinal product used for certain rheumatological and haematological disorders, is currently limited worldwide. The Federal Agency for Medicines and Health Products (FAMHP) therefore issues recommendations.
Source: FAMHP
The company Roche, holder of the marketing authorisation for the medicinal product RoActemra (toculizimab), has informed the FAMHP that supply problems may occur between July and the end of December 2021. The current production capacity is insufficient to meet demands and the stock will be centrally managed. That way the firm tries to limit the unavailability per country to one month.